David W. Dodick M.D. Professor Director of Headache Medicine Department of Neurology Mayo Clinic Phoenix Arizona USA
|
|
- Amberly McCoy
- 5 years ago
- Views:
Transcription
1 Headache Masters School 2013 in Asia Sunday March 24, 2013 Procedural Medicine Workshop Onabotulinumtoxin A: Evidence, Injection Technique, and Mechanism of Action David W. Dodick M.D. Professor Director of Headache Medicine Department of Neurology Mayo Clinic Phoenix Arizona USA 1
2 Learning objectives 1. Describe the diagnostic criteria for chronic migraine and the rationale for the change between ICHD II and ICHD III 2. Provide an overview of the evidence base for the treatment of chronic migraine and trigeminal neuralgia 3. Explain the potential mechanisms of action underlying the efficacy of OnabotulinumtoxinA in chronic migraine 2
3 Chronic Migraine and Medication Overuse Headache ICHD II and ICHD III ICHD II 1 ± medication overuse 2 combined criteria Headache on 15 days per month for at least 3 months 1 5 prior migraine attacks 1 On 8 days per month, headache fulfills criteria for migraine without aura and/or relieved with triptans or ergotamine Not attributed to another causative disorder 1 In case of medication overuse, diagnosis is MOH ICHD III (in press) Headache 15 days per month for at least 3 months On >8 days per month, headache fulfills MO, MA, or relieved with triptan or ergot Patients who fulfill criteria for CM and overuse medications, receive two diagnosis (CM 1.3 and MOH 8.2) 3
4 Chronic migraine Diagnosis Headache > 15d/mo Headache > 15d/mo Exclude secondary cause Diagnosis migraine > 8 days meeting criteria for migraine 4 *GMAP recommendation 1. Headache Classification Committee. Olesen J et al. Cephalalgia 2006;26: Silberstein SD et al. Cephalalgia 2005;25:
5 The majority of chronic migraine (CM) sufferers in the population do not remit Annual incidence % Transition Rates in 2006 and 2007 Relative to CM Status in 2005 (Baseline) Remitted CM 26% Persistent CM 22% Transitioning CM 52% 5 AMPP = American Migraine Prevalence and Prevention. Lipton RB. Headache 2011;51:77 83.
6 Peripheral and Central Sensitization in Chronic Migraine Ophthalmic Nerve Occipital Nerves Dura Trigeminal Cervical Complex (TCC) Trigeminal Ganglion 6 1. Netter FH. Atlas of Human Anatomy. Summit, NJ: CIBA-GEIGY Corporation; Goadsby PJ et al. N Engl J Med. 2002;346:
7 Preventive Treatments in chronic migraine: Evidence base Treatment Anticonvulsants: Valproate Topiramate Gabapentin Levetiracetam Evidence for Use in Chronic Migraine Small DBPC and comparator trial in CM/CDH 1,2 Three DBPC trials in CM 3,4 One DBPC trial in CDH 5 One DBPC trial in CDH 10 Antidepressants: Amitriptyline Fluoxetine Tizanidine Neuromodulation Small open label trial in TM 6 Small DBPC trial in CDH 7 Small DBPC trial in CDH 8 Sham controlled trials of occipital nerve stimulation (ONS) OnabotulinumtoxinA Two DBPC trials in CM 9 DBPC = double blind placebo controlled; TM = transformed migraine; CDH = chronic daily headache; CM = chronic migraine.1. Yurekli VA et al. J Headache Pain. 2008;9: Bartolini M et al. Clin Neuropharmacol. 2005;28: Diener HC et al. Cephalalgia. 2007;27: Silberstein SD et al. Headache. 2007;47: Spira PJ, Beran RG. Neurology. 2003;61: Krymchantowski AV et al. Headache. 2002;45: Saper JR et al. Headache. 1994;34: Saper JR et al. Headache. 2002;42: Dodick DW et al. Headache. 2010;50: ; Beran RG, Spira PJ. Cephalalgia 2010; 31(5) Saper JR, et al. Cephalalgia 2011 Feb;31(3):271 85, Silberstein SD, et al. Cephalalgia 2011;31:117. Lipton RB, et al. Cephalalgia 2009;suppl 1:30. 7
8 OnabotulinumtoxinA for Chronic Migraine 8
9 Anatomical Injection Sites Follow Distributions and Areas Innervated by the Trigeminal and Cervical Sensory System Auriculotemporal Nerve Supratrochlear Nerve Supraorbital Nerve Greater Occipital Nerve Lesser Occipital Nerve Cervical Rami 9 9 Schuenke M et al, eds. Theime Atlas of Anatomy: Head and Neuroanatomy. Stuttgart: Thieme; 2010.
10 Injection Sites: Corrugator and Procerus 5 U ONABA (0.1 ml injected) Procerus: 5 U at site Corrugator: 5 U at each site Blumenfeld A, Silberstein SD, Dodick DW, et al. Headache Oct; 50(9):
11 Injection Site: Frontalis Region 5 U ONABA (0.1 ml injected) Blumenfeld A, Silberstein SD, Dodick DW, et al. Headache Oct; 50(9):
12 Injection Sites: Temporalis 5 U ONABA (0.1 ml injected) Blumenfeld A, Silberstein SD, Dodick DW, et al. Headache Oct; 50(9):
13 Injection Site: Occipitalis 5 U ONABA (0.1 ml injected) Occipitalis muscles and injection sites* Sternocleidomastoid muscle Nuchal ridge Blumenfeld A, Silberstein SD, Dodick DW, et al. Headache Oct; 50(9):
14 Injection Sites: Cervical Paraspinal and Trapezius 5 U ONABA (0.1 ml injected) Cervical paraspinal 5 U each* Trapezius muscles 5 U each Semispinalis capitus Splenius capitus Trapezius Levator scapulae Blumenfeld A, Silberstein SD, Dodick DW, et al. Headache Oct; 50(9):
15 Injection Paradigm: Required Dose Using a Fixed Site, Fixed Dose Paradigm Order Muscle Number of Units (U) A Corrugator 10 (5 each side) B Procerus 5 C Frontalis 20 (10 each side) D Temporalis 40 (20 each side) E Occipitalis 30 (15 each side) F Cervical paraspinal 20 (10 each side) G Trapezius 30 (15 each side) Total number of units (U) Blumenfeld A, Silberstein SD, Dodick DW, et al. Headache Oct; 50(9):
16 Follow the pain strategy D. Temporalis: 5 U/site (up to 2 additional sites) E. Occipitalis: 5 U/site (up to 2 additional sites) G. Trapezius: 5 U/site (up to 4 additional sites) 16
17 PREEMPT: Pooled baseline demographics Reflects Clinical Population OnabotulinumtoxinA (n=688) Placebo (n=696) Mean age, years Mean years since onset of CM Female, % Mean HA days (SD) 20 (4) 20 (4) Mean migraine days (SD) 19 (4) 19 (4) Mean moderate/severe HA days (SD) 18 (4.1) 18 (4.3) Mean cumulative hours of HA occurring on HA days (SD) 296 (117)* 281 (115)* % Patients with severe ( 60) HIT 6 score % Patients overusing acute HA pain medication HA = headache; HIT = Headache Impact Test. *p<0.05. Dodick DW et al. Headache. 2010;50:
18 PREEMPT pooled analysis: Change in headache days primary endpoint 1 Week: Headache Days/28 Days (Mean Headache Change Days/28 From Baseline) Days p<0.001 Week 24 Primary Endpoint p<0.001 p<0.001 p<0.001 p<0.001 Double Blind Phase p<0.001 OnabotulinumtoxinA Placebo p<0.001 p=0.008 p=0.01 p=0.007 p=0.047 p=0.019 Open Label Phase p=0.011 p= *Patients who received onabotulinumtoxina throughout the 56 week treatment program. Mean ± standard error. The double blind phase included 688 subjects in the onabotulinumtoxina group and 696 in the placebo group. Headache days at baseline: 19.9 onabotulinumtoxina group vs 19.8 placebo group, p= Aurora et al. Headache (9):
19 OnabotulinumtoxinA: Primary and secondary outcomes in PREEMPT studies Endpoint, Mean Change From Baseline OnabotulinumtoxinA (n=688) Placebo (n=696) P value* Frequency of HA days <0.001 Frequency of migraine days <0.001 Frequency of moderate/severe HA days <0.001 Total cumulative HA hours on HA days <0.001 % Patients with severe ( 60) HIT 6 score <0.001 Total HIT 6 score <0.001 Frequency of HA episodes Frequency of migraine episodes Frequency of acute HA pain medication intake (all categories) Frequency of triptan use < * p values are adjusted for baseline and for medication overuse stratification. HA = headache; HIT = Headache Impact Test. Dodick DW et al. Headache. 2010;50:
20 PREEPMT studies: Responder rates ( 50%) At Week 56, ~70% of patients achieved 50% reduction in headache days 1 and migraine days 2 (from baseline) OnabotulinumtoxinA (n=688) Placebo (n=696) Week 24 Patients (%) p<0.001 p<0.001 Headache Days 1 Migraine Days 2 20 Headache days at baseline: 19.9 onabotulinumtoxina group vs 19.8 placebo group, p= Migraine days at baseline: 19.1 onabotulinumtoxina group vs 18.9 placebo group, p= Dodick DW et al. Headache. 2010; 50:
21 PREEPMT studies: Responder rates ( 75%) OnabotulinumtoxinA (n=688) Placebo (n=696) p=0.002 p=0.007 p=0.005 p=0.006 p<0.001 p<0.001 Percent of Patients Headache Days Headache Episodes Mod/Severe Headache Days Total Cumulative Hours of HA on HA Days Migraine Days Migraine Episodes 21 Dodick DW. et al. IHC Berlin June 2011.
22 PREEMPT pooled analysis: subgroup who overuse acute pain medications OnabotulinumtoxinA (n=445) Placebo (n=459) Change in Frequency From Baseline Headache Days Improvement 22 *Of the total pooled PREEMPT population, 64.7% and 65.9% of onabotulinumtoxina and placebo groups, respectively, overused acute headache pain medication (simple analgesics, ergotamine/dhe, triptans, opioids, combination of analgesics, or any combination of the preceding classes). 1,2 p< Silberstein SD et al. Presented at IHC Dodick DW et al. Headache. 2010;50:
23 PREEMPT: Analysis of Responders Despite Initial Non Response 50% First Time Responders,* Variable OnabotulinumtoxinA (n=688) Frequency of HA days, n (%) 339 (49.3) 78 (11.3) 71 (10.3) Frequency of moderate/severe HA days 365 (53.1) 90 (13.1) 59 (9.6) Total cumulative hours of HA on HA days 373 (54.2) 90 (11.6) 51 (7.4) *First time responders for a given time point are subjects who never responded at any previous time points. 23 Silberstein SD, Dodick DW, Turkel C, et al. EHMTIS 2012
24 PREEMPT: OnabotulinumtoxinA is a well tolerated treatment for chronic migraine No new treatment related AEs were identified Most AEs were mild or moderate in severity and resolved without sequelae OnabotulinumtoxinA (n = 687) Placebo (n = 692) Neck pain 60 (8.7) 19 (2.7) Muscular weakness 24 (5.5) 2 (0.3) Headache 32 (4.7) 22 (3.2) Migraine 26 (3.8) 18 (2.6) Musculoskeletal stiffness 25 (3.6) 6 (0.9) Eyelid ptosis 25 (3.6) 2 (0.3) Injection site pain 23 (3.3) 14 (2.0) Myalgia 21 (3.1) 6 (0.9) Musculoskeletal pain 18 (2.6) 10 (1.4) Facial paresis 15 (2.2) 0 (0.0) 24 Dodick DW et al. Headache. 2010; 50:
25 Treatment effect size 50% Responder Rate (Active / Placebo); NNT Discontinuation Due to Adverse Events Migraine/ Migrainous Days; Absolute Between Group Difference OnabotulinumtoxinA 1 47% / 35%* 8 3.8% 8.2 (2.0) Topiramate 2,3 37% / 29% * % 6.4 (1.7) 25 * 50% reduction in mean monthly migraine days. These were not comparison studies. The topiramate data come from a double blind study assessing topiramate efficacy in Chronic Migraine patients, and the onabotulinumtoxina data come from the pooled results of the PREEMPT studies. NNT = Number Needed to Treat. 1. Dodick DW et al. Headache. 2010:50: Silberstein SD et al. Headache. 2009;49:
26 OnabotulinumtoxinA and Pain OnabotA relieves pain in variety of conditions (e.g. spasticity, back pain, trigeminal neuralgia, neuropathic pain) Bilateral effects from unilateral injection in experimental neuropathy; suggests central site of action 5 OnabotA inhibits sensitization of central V1 neurons in animal/human pain models Oshinsky ML et al. Cephalalgia. 2004;24:781 (PA.21). 2. Cui M et al. Naunyn Schmiedebergs Arch Pharmacol. 2002;365:R17 (#33). 3. Aoki KR. Headache. 2003;43(suppl 1):S9 S Gazerani P et al. Pain. 2006;122: ; Gazerini M, et al. Pain 2009;141: Bach Rojeckly L, et al. Eur J Pharmacol 633:10 14
27 Onabotulinumtoxin A Peripheral Mechanism of Action 27
28 OnabotulinumtoxinA May Access Dural Afferent Nociceptors in Dermis/Subcutaneous Tissue Action potential Reduction in primary sensory afferent signals from the meninges, bone and scalp 28 Kosaras B, et al. J Comp Neurol 2009;515:
29 Directionality of Pain as a Predictor of Response Intracranial origin Extracranial origin 29 Jakubowski M., et al. Pain 125 (2006)
30 Onabotulinumtoxin A Central Mechanism of Action 30
31 Antinociceptive Effect in Trigeminal System is Centrally Mediated and Dependent on Axonal Transport 31 Matak I, et al. Neurosci 2011;86:
32 Transport is Time, Location, and Dose Dependent May Explain Clinical Effects 32 Matak I, et al. Neurosci 2011;86:
33 OnabotulinumtoxinA for Trigeminal Neuralgia 75u/1.5ml 33 Wu C et al. Cephalalgia 2012;
34 OnabotulinumtoxinA for Trigeminal Neuralgia Weekly mean VAS scores Mean attack frequency per day *Responders 68% vs 15% 34 * Responder = >50% reduction in pain score Wu C et al. Cephalalgia 2012;
35 Secondary Endpoint (Patient Global Impression of Change) and Adverse Events Adverse Events 5 patients (OnabotA) with facial asymmetry resolved 7 weeks 3 patients with transient facial edema (2 OBA/ 1 placebo) 35
36 OnabotulinumtoxinA for Headache and Facial Pain Evidence supports the safety and efficacy of OnabotulinumtoxinA for Chronic Migraine Evidence emerging for efficacy of OnabotA for trigeminal neuralgia Mechanism of action unclear, but could be indirect or direct inhibition of central 2 nd order trigeminal sensory neurons 36
11/10/2017 HEADACHE INJECTIONS WORKSHOP. Comprehensive Migraine Education Program Procedural Curriculum Developers. Disclosures
HEADACHE INJECTIONS WORKSHOP Saturday, November 18 and Sunday, November 19 Scottsdale Headache Symposium Comprehensive Migraine Education Program Procedural Curriculum Developers PROGRAM CHAIRS David W.
More information6/20/2018 PROCEDURAL TREATMENTS FOR HEADACHE. Case study: Emily. Diary
Headache severity (Scale 0 10) Topiramate started on July 20, D/C July 29 Amitriptyline initiated, D/C on Sep 23 PROCEDURAL TREATMENTS FOR HEADACHE Andrew M. Blumenfeld Director of the Headache Center
More informationHEADACHE INJECTIONS WORKSHOP
HEADACHE INJECTIONS WORKSHOP Comprehensive Migraine Education Program Procedural Curriculum Developers PROGRAM CHAIRS David W. Dodick, MD, FAHS Mayo Clinic College of Medicine Richard B. Lipton, MD, FAHS
More informationMark W. Green, MD, FAAN
Mark W. Green, MD, FAAN Professor of Neurology, Anesthesiology, and Rehabilitation Medicine Director of Headache and Pain Medicine Icahn School of Medicine at Mt Sinai New York Pain-sensitive structures
More information10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY
BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES JENNIFER SHIN, PHARMD PGY2 AMBULATORY CARE PHARMACY RESIDENT COMMUNITYCARE HEALTH CENTERS PHARMACOTHERAPY ROUNDS OCTOBER 20, 2017
More informationNational Institute for Health and Clinical Excellence. Single Technology Appraisal (STA)
National Institute for Health and Clinical Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine
More informationBotox for Chronic Migraine: Tips and Tricks
Botox for Chronic Migraine: Tips and Tricks Ten Questions for Andrew M. Blumenfeld, MD Andrew M. Blumenfeld is director of The Headache Center of Southern California. Most of his research has focused on
More informationBotulinum Neurotoxin for Chronic Migraine and Trigeminal Neuralgia
Botulinum Neurotoxin for Chronic Migraine and Trigeminal Neuralgia David W. Dodick, MD Professor Department of Neurology, Mayo Clinic Phoenix Arizona, USA Onabotulinumtoxin A is the only botulinum toxin
More informationChronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary
Chronic Migraine in Primary Care December 11 th, 2017 Werner J. Becker University of Calgary Disclosures Faculty: Werner J. Becker Relationships with commercial interests: Grants/Research Support: Clinical
More informationBotox (Botulinum toxin type A) in the prophylaxis of headaches in chronic migraine
Botox (Botulinum toxin type A) in the prophylaxis of headaches in chronic migraine Manufacturer responses to clarification questions from the Evidence Review Group November 2011 Clarification on manufacturer
More informationWhat is the Effectiveness of OnabotulinumtoxinA (Botox ) in Reducing the Number of Chronic Migraines (CM) in Patients Years Old?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2013 What is the Effectiveness of OnabotulinumtoxinA
More informationAalborg Universitet. Botulinum neurotoxin A for chronic migraine headaches Cairns, Brian Edwin; Gazerani, Parisa. Published in: Pain Management
Aalborg Universitet Botulinum neurotoxin A for chronic migraine headaches Cairns, Brian Edwin; Gazerani, Parisa Published in: Pain Management DOI (link to publication from Publisher): 10.2217/PMT.14.30
More informationOnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study
OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study The Harvard community has made this article openly available. Please share how this access benefits you. Your story
More informationปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา
ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา 1 CONTENT 1 2 3 Chronic Daily Headache Medical Overused Headache Management Headaches are one of the most common symptoms List
More informationSupraorbital nerve stimulation Cefaly Device - FDA Approved for migraine prevention (also being investigated as acute therapy)
NEUROSTIMULATION/NEUROMODULATION UPDATE Meyer and Renee Luskin Andrew Charles, M.D. Professor Luskin Chair in Migraine and Headache Studies Director, UCLA Goldberg Migraine Program David Geffen School
More informationExpert Opinion. OnabotulinumtoxinA for Chronic Migrainehead_2071 CLINICAL HISTORY. Andrew Blumenfeld, MD; Randolph W. Evans, MD
142..148 Headache 2011 American Headache Society ISSN 0017-8748 doi: 10.1111/j.1526-4610.2011.02081.x Published by Wiley Periodicals, Inc. Expert Opinion OnabotulinumtoxinA for Chronic Migrainehead_2071
More informationSpecific Objectives A. Topics to be lectured and discussed at the plenary sessions
Specific Objectives A. Topics to be lectured and discussed at the plenary sessions 0. Introduction: Good morning ICHD-III! Let s start at the very beginning. When you read you begin with A-B-C, so when
More information10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD
Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD } Depomed Consultant 2014 to present } Avanir Consultant 2014 to present } Amgen
More informationViews and Perspectives
Headache ISSN 0017-8748 VC 2017 Allergan plc. Headache published by Wiley Periodicals, Inc. doi: 10.1111/head.13074 on behalf of American Headache Society Published by Wiley Periodicals, Inc. Views and
More informationChronic daily headache (CDH), defined
FINDING A FIT: STRATEGIES FOR CHRONIC MIGRAINE PROPHYLAXIS David W. Dodick, MD, FRCP(C), FACP ABSTRACT Chronic daily headache (CDH) affects approximately 4% to 5% of the population and is responsible for
More informationDoes analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse
DOI 10.1186/s40064-015-1386-8 RESEARCH Open Access Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse Fayyaz Ahmed *, Hassan
More informationIs OnabotulinumtoxinA Good for Other Head and Face Pain? Disclosures BoNT/A for non- CM Botulinum neurotoxin (BoNT) in clinical use for headache >20
1 2 3 4 5 6 Is OnabotulinumtoxinA Good for Other Head and Face Pain? Disclosures BoNT/A for non- CM Botulinum neurotoxin (BoNT) in clinical use for headache >20 years Efficacy of BoNT type A (onabotulinumtoxina,
More information6/2/2017. Objectives. Statement of Problem: Migraine Headaches Are Common. Chronic Headache In Pediatrics, Botox and Beyond
Chronic Headache In Pediatrics, Botox and Beyond Ken Mack MD PhD Mayo Clinic 2015 MFMER slide-1 Objectives Understand pediatric chronic headache presentations Review evidence for the treatment of chronic
More informationHeadache: Using Neuromodulation as Therapy
Headache: Using Neuromodulation as Therapy Rashmi Halker, MD, FAHS Assistant Professor of Neurology Department of Neurology Mayo Clinic Phoenix Arizona Disclosures Nothing to disclose 2013 MFMER slide-2
More informationOnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience
731521TAN0010.1177/1756285617731521Therapeutic Advances in Neurological DisordersC-C Chiang and AJ Starling research-article2017 Therapeutic Advances in Neurological Disorders Review OnabotulinumtoxinA
More informationAleksandra Radojičić. Headache Center, Neurology Clinic, Clinical Center of Serbia
European Headache School Belgrade 2012 MEDICATION OVERUSE HEADACHE Aleksandra Radojičić Headache Center, Neurology Clinic, Clinical Center of Serbia Historical data First cases were described in XVII century
More informationThe effects of greater occipital nerve block and trigger point injection on brush allodynia and pain in migraine
Thomas Jefferson University Jefferson Digital Commons Department of Neurology Faculty Papers Department of Neurology April 2005 The effects of greater occipital nerve block and trigger point injection
More information2 nd Resubmission. 13 January 2017
2 nd Resubmission botulinum toxin A, 50 Allergan units, 100 Allergan units, 200 Allergan units, powder for solution for injection (Botox ) SMC No. (692/11) Allergan Limited 13 January 2017 The Scottish
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
CGRP Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests
More information1/25/2018 ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Disclosures: Objectives: Headache Division
ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Lawrence C Newman, MD, FAHS, FAAN Clinical Professor of Neurology Disclosures: Advisory Board: Alder, Allergan, Amgen, Lilly, Supernus,
More informationThe majority of primary headaches fall into
NEUROTOXINS Neurotoxins: Expanding Uses of Neuromodulators in Medicine Headache Edward Nahabet, BA Jeffrey E. Janis, MD, FACS Bahman Guyuron, MD, FACS Cleveland and Columbus, Ohio Summary: Over the course
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
CGRP Page 1 of 8 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests
More informationOnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm
Pedraza et al. SpringerPlus (2015) 4:176 DOI 10.1186/s40064-015-0957-z a SpringerOpen Journal RESEARCH Open Access OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with
More informationMedical Policy. Description/Scope. Position Statement. Rationale
Subject: Document#: Current Effective Date: 06/28/2017 Status: Reviewed Last Review Date: 05/04/2017 Description/Scope This document addresses occipital nerve stimulation (ONS), which involves delivering
More informationAn Overview of MOH. ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California
An Overview of MOH IHS ASIAN HA MASTERS SCHOOL MARCH 24, 2013 ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California President-Elect
More informationDefining the Differences Between Episodic Migraine and Chronic Migraine
Curr Pain Headache Rep (2012) 16:86 92 DOI 10.1007/s11916-011-0233-z CHRONIC DAILY HEADACHE (SJ WANG, SECTION EDITOR) Defining the Differences Between Episodic Migraine and Chronic Migraine Zaza Katsarava
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationGiorgio Sandrini Armando Perrotta Cristina Tassorelli Paola Torelli Filippo Brighina Grazia Sances Giuseppe Nappi
J Headache Pain (2011) 12:427 433 DOI 10.1007/s10194-011-0339-z ORIGINAL Botulinum toxin type-a in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled,
More informationWhat is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary
What is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary Overview Understanding the burden Commonly used terms Acute therapy What we currently have What we are going
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP, ACONP and AOAAM:
More informationA two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
Negro et al. The Journal of Headache and Pain (2016) 17:1 DOI 10.1186/s10194-016-0591-3 RESEARCH ARTICLE A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache:
More informationImplanted Auriculotemporal Nerve Stimulator for the Treatment of Refractory Chronic Migrainehead_
1064 June 2010 22. Fusco M, D Andrea G, Miccichè F, Stecca A, Bernardini D, Cananzi AL. Neurogenic inflammation in primary headaches. Neurol Sci. 2003;24(Suppl. 2):S61-S64. 23. Shibagaki Y, Fujita T. Thrombotic
More informationBotulinum toxin type A is currently being
EMERGING PREVENTIVE OPTIONS FOR CHRONIC DAILY HEADACHE * David W. Dodick, MD, FRCP(C), FACP ABSTRACT Approximately 3% to 5% of the population is affected by headaches on a daily or almost daily basis.
More informationBy Nathan Hall Associate Editor
By Nathan Hall Associate Editor 34 Practical Neurology March 2005 These new rules may change the definition of head pain, but some practitioners may find the new guidelines themselves to be a source of
More informationASPS Insurance Coverage Criteria for Third-Party Payers Nerve Decompression for Migraine Surgery
ASPS Insurance Coverage Criteria for Third-Party Payers Nerve Decompression for Migraine Surgery BACKGROUND Migraine headache is a debilitating neurovascular disorder that affects 35 million Americans
More informationHeadache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, II. Management of Refractory Headaches
Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, 2016 II. Management of Refractory Headaches Case presentation 1: A case of intractable daily-persistent headache Keio University School
More informationDisclosure. Learning Objectives 11/10/2017. The Best and Most Interesting Research from Last Year Cephalalgia
The Best and Most Interesting Research from Last Year Cephalalgia David W. Dodick, M.D. Department of Neurology Mayo Clinic Scottsdale Arizona Disclosure Consulting services: Acorda, Allergan, Amgen, Alder,
More informationPrednisone vs. placebo in withdrawal therapy following medication overuse headache
doi:10.1111/j.1468-2982.2007.01488.x Prednisone vs. placebo in withdrawal therapy following medication overuse headache L Pageler 1,2, Z Katsarava 2, HC Diener 2 & V Limmroth 1,2 1 Department of Neurology,
More informationChronic Daily Headaches
Chronic Daily Headaches ANWARUL HAQ, MD, MRCP(UK), FAHS DIRECTOR BAYLOR HEADACHE CENTER, DALLAS, TEXAS DISCLOSURES: None OBJECTIVES AT THE CONCLUSION OF THIS ACTIVITY, PARTICIPANTS WILL BE ABLE TO: define
More informationDescription. Section: Surgery Effective Date: January 15, 2016 Subsection: Surgery Original Policy Date: December 6, 2012 Subject:
Last Review Status/Date: December 2015 Description Page: 1 of 11 Surgical deactivation of trigger sites is a proposed treatment of migraine headache. The procedure involves identifying a patient s predominant
More informationResearch Submission. Accepted for publication December 14, 2004.
Research Submission Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double-Blind, Placebo-Controlled
More informationBotulinum toxin type A for the prevention of headaches in adults with chronic migraine
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine Issued: June 2012 guidance.nice.org.uk/ta260 NICE has accredited the process used by the Centre for Health Technology
More informationMigraine Research Update Clinical and Scientific Highlights. David W. Dodick M.D. Professor Department of Neurology Mayo Clinic Phoenix Arizona
Migraine Research Update Clinical and Scientific Highlights David W. Dodick M.D. Professor Department of Neurology Mayo Clinic Phoenix Arizona 1 Objective Discuss some of the important advances in clinical
More information8/6/18. Patient Experience. effective management of Chronic Migraine and Occipital Neuralgia in the Post 9/11 Combat Veteran
8//8 Patient Experience Validation of practice based evidence for effective management of Chronic Migraine and Occipital Neuralgia in the Post 9/ Combat Veteran Karen Williams,MSN, RN, FNP-BC Neurology/Headache
More informationClinical case. Clinical case 3/15/2018 OVERVIEW. Refractory headaches and update on novel treatment. Refractory headache.
OVERVIEW Refractory headaches and update on novel treatment Definition of refractory headache Treatment approach Medications Neuromodulation In the pipeline Juliette Preston, MD OHSU Headache Center Refractory
More informationBotulinum toxins: abobotulinumtoxina (Dysport ), incobotulinumtoxina (Xeomin ), onabotulinumtoxina (Botox ), & rimabotulinumtoxinb (Myobloc )
Botulinum toxins: abobotulinumtoxina (Dysport ), incobotulinumtoxina (Xeomin ), onabotulinumtoxina (Botox ), & rimabotulinumtoxinb (Myobloc ) These services may or may not be covered by your HealthPartners
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: surgical_deactivation_of_migraine_headache_trigger_sites 10/2012 5/2017 5/2018 5/2017 Description of Procedure
More informationMigraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification
28 Primary Care Medicine Principles and Practice 29 October 28 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Department of Neurology Headache International Headache Society Classification
More informationZonisamide for migraine prophylaxis in refractory patients
Thomas Jefferson University Jefferson Digital Commons Department of Neurology Faculty Papers Department of Neurology March 2006 Zonisamide for migraine prophylaxis in refractory patients Avi Ashkenazi
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Surgical Deactivation of Headache Trigger Sites Page 1 of 12 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Surgical Deactivation of Headache Trigger Sites Professional
More informationAdvances in the Treatment of Migraine
Advances in the Treatment of Migraine C. Philip O Carroll, M.D. Director Neurobehavioral Medicine Hoag Neurosciences Institute Guyuron B Headache, 2015;55:1464-1473 I m sorry your head hurts, sweetie.is
More informationJournal of Anesthesia & Pain Medicine
Case Report To spasm, or Not to Spasm, That is the Question Journal of Anesthesia & Pain Medicine John C McDonald BA 1 and Terence K Gray DO 1,2* 1 Mercy Pain Center, Mercy Hospital, Portland, Maine, USA
More informationGet ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention
Get ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention Amanda Janisch, PharmD PGY2 Ambulatory Care Pharmacy Resident MCHS SWMN, Mankato, MN 2018 MFMER slide-1 Disclosures No financial interest
More informationThe frequency with which migraine attacks
STRATEGIES TO PREVENT MIGRAINE * Sheena K. Aurora, MD ABSTRACT Patients who suffer from daily or near-daily headaches may experience significant disability and interference in all aspects of their professional
More informationLevetiracetam in the Preventive Treatment of Transformed Migraine: A Prospective, Open-Label, Pilot Study
VOLUME 66, NUMBER 3, MAY/JUNE 2005 Levetiracetam in the Preventive Treatment of Transformed Migraine: A Prospective, Open-Label, Pilot Study Alan M. Rapoport, MD1,2; Fred D. Sheftell, MD2,3; Stewart J.
More informationCGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS)
CGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS) Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Germany CGRP, Monoclonal Antibodies and Small Molecules
More informationMigraine - whats on the horizon
Managing your migraine Edinburgh Saturday 10 th March 2018 Migraine - whats on the horizon Alok Tyagi Consultant Neurologist Glasgow Disclaimer I have received from Janssen Cillag, GSK, Allergan, Electrocore,
More informationHeadache Pain Generators
Objectives 1. Define the major categories of headache. 2. Take a history directed at characterizing a headache pattern in an individual patient and identify the cause or triggers of the headache. 3. Understand
More informationNothing to disclose 3
Nothing to disclose 3 PREVALENCE AND BURDEN OF HEADACHE Patient with CDH IHS migraine Recurrent severe headache Severe headache Episodic headache Have had headache Entire population CDH=chronic daily headache.
More informationTears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE
Tears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE IHS Classification 1989 (updated 2004) Primary Headaches 4 categories Migraine Tension-type Cluster and other trigeminal
More informationSinem Zeybek, Aysin Kisabay, U Serpil Sari, Deniz Selcuki. Department of Neurology, Medical Faculty, Celal Bayar University, Manisa, Turkey.
Neurology Asia 2018; 23(1) : 35 43 Evaluation of the effect of botulinum neurotoxin type A (BoNT/A) on daily activity performance in chronic migraine patients using VAS, MIDAS AND HIT-6 tests Sinem Zeybek,
More informationHeadache. Section 1. Migraine headache. Clinical presentation
Section 1 Headache Migraine headache 1 Clinical presentation It is important to recognize just how significant a problem migraine headache is. It has been estimated that migraine affects 11% of the United
More informationEmbriologically, The head is formed from the first two cervical segments (except the mandible, which is formed by the third). The first and second
Embriologically, The head is formed from the first two cervical segments (except the mandible, which is formed by the third). The first and second cervical vertebra are also derived from these two segments.
More informationSandler Family Trust. UCSF Medical Center. Headache A Review and Update. Headache The burden. Headache Group, UCSF Disclosure- by proportion*
1 Headache A Review and Update Advances in Internal Medicine June 29 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Headache Group, UCSF Disclosure- by proportion Sandler Family Trust UCSF
More informationHeadache A Practical Approach
Headache A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache and Pain Development Teams Disclosures:
More informationTopiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders
J Headache Pain (2012) 13:53 59 DOI 10.1007/s10194-011-0395-4 ORIGINAL Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders Abouch Valenty Krymchantowski
More informationYuecheng Yang, Xuehua Huang, Yinghui Fan, Yingwei Wang, and Ke Ma. 1. Introduction
Evidence-Based Complementary and Alternative Medicine Volume 2015, Article ID 690856, 7 pages http://dx.doi.org/10.1155/2015/690856 Research Article Efficacy of Pulsed Radiofrequency on Cervical 2-3 Posterior
More informationPer cent of patients with chronic migraine who responded per onabotulinumtoxina treatment cycle: PREEMPT
Migraine 1 Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA 2 Department of Neurology, Mayo Clinic Arizona, Phoenix, Arizona, USA 3 Department of Neurology and Neurological
More informationMigraine Management. Roger Cady, MD Headache Care Center Springfield, MO
Migraine Management Roger Cady, MD Headache Care Center Springfield, MO Disclosures Objectives The evolution of migraine From benign episodic (benign) headache to potentially a devastating chronic disease
More informationEmerging Challenges in Primary Care: Brainstorm: A Symposium on Migraine Treatment and Management
Emerging Challenges in Primary Care: 2017 Brainstorm: A Symposium on Migraine Treatment and Management 1 Faculty Jeff Unger, MD, ABFM, FACE Director, Unger Primary Care Medical Group Rancho Cucamonga,
More informationHeadache and Facial Pain. Mohammed ALEssa MBBS, FRCSC Assistant Professor Consultant Otolaryngology,Head & Neck Surgical Oncology
Headache and Facial Pain Mohammed ALEssa MBBS, FRCSC Assistant Professor Consultant Otolaryngology,Head & Neck Surgical Oncology Introduction It is the most common neurologic complain The diagnosis usually
More informationNeurostimulation 2016
Neurostimulation 2016 Stephen D Silberstein, MD Jefferson Headache Center Thomas Jefferson University Hospital Philadelphia, PA 1 Neuromostimulation Occipital Nerve Stimulation (ONS) Transcranial Magnetic
More informationHarold G. Wolff Lecture Award Winner
Headache 2008 the Authors Journal compilation 2008 American Headache Society ISSN 0017-8748 doi: 10.1111/j.1526-4610.2008.01217.x Published by Wiley Periodicals, Inc. Harold G. Wolff Lecture Award Winner
More informationRefractory Headache Challenges and Strategies. David W. Dodick, M.D. Department of Neurology Mayo Clinic Phoenix Arizona USA
Refractory Headache Challenges and Strategies David W. Dodick, M.D. Department of Neurology Mayo Clinic Phoenix Arizona USA Headache Masters School, Tokyo 2013 Definition of refractory/intractability depends
More informationEffectiveness of Pharmacological Treatments in Imploding vs. Exploding Headaches
Effectiveness of Pharmacological Treatments in Imploding vs. Exploding Headaches Item Type Thesis Authors Hunt, Megan Publisher The University of Arizona. Rights Copyright is held by the author. Digital
More informationA New Era of Migraine Management: The Challenging Landscape in Prevention
Provided by MediCom Worldwide, Inc. Supported by an educational grant from Teva Pharmaceuticals What is a Neuropeptide? Small chains of amino acids released by neural cells (neurons or glial cells) to
More informationA case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau:
Chronic Daily Headache Bassel F. Shneker, MD, MBA Associate Professor Vice Chair, OSU Neurology The Ohio State University Wexner Medical Center Financial Disclosures None related to the presentation Grants
More informationMedication Prior Authorization Form
(OnabotulinumtoxinA) Dysport (abobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Xeomin (incobotulinumtoxina) Policy Number: 1042 Policy History Approve Date: 12/11/2015 Revise Dates: 7/7/2016 Next Review:
More information10/19/12. Post-Traumatic Headache. Lawrence J. Horn, MD Disclosures. Speakers Bureau: Allergan, Inc.
10/19/12 Post-Traumatic Headache Professor and Interim Chair, Department of PM&R Wayne State University School of Medicine Detroit, MI Medical Director Neuroscience Rehabilitation Institute of Michigan
More informationChronic Migraine: Opioid and Non-Opioid Treatment
Chronic Migraine: Opioid and Non-Opioid Treatment By: Matthew Kozminski, DO, FAHS Board Certified in Neurology by the American Board of Psychiatry and Neurology Certified in Headache Medicine by the United
More informationTrigeminal Autonomic Cephalalgias. Disclosures. Objectives 6/20/2018. Rashmi Halker Singh, MD FAHS UCNS Review Course June 2018
Trigeminal Autonomic Cephalalgias Rashmi Halker Singh, MD FAHS UCNS Review Course June 2018 Disclosures Honoraria from Allergan and Amgen for advisory board, Current Neurology and Neuroscience Reports
More informationOccipital Nerve Blockage in Cervicogenic Headache: A case Report and Brief Review of Literature
Occipital Nerve Blockage in Cervicogenic Headache: A case Report and Brief Review of Literature Tuba Tulay Koca Department of Physical Medicine and Rehabilitation, State Hospital, Malatya, Turkey Abstract
More informationUpdate on Diagnosis and Management of Migraines
Update on Diagnosis and Management of Migraines Joel J. Heidelbaugh, MD, FAAFP, FACG Clinical Professor Departments of Family Medicine and Urology University of Michigan Learning Objectives To distinguish
More informationDespite the widespread use of triptans ... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability
... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability Randal L. Von Seggern, PharmD, BCPS Abstract Objective: This article summarizes preclinical and clinical data for
More informationPeripheral Nerve S-mula-on
Peripheral Nerve S-mula-on Konstan-n Slavin, MD Professor, Department of Neurosurgery University of Illinois at Chicago Peripheral Nerve S-mula-on New (?) approach Neuropathic pain syndromes Off label
More informationDisclosures. Objectives 6/2/2017
Classification: Migraine and Trigeminal Autonomic Cephalalgias Lauren Doyle Strauss, DO, FAHS Assistant Professor, Child Neurology Assistant Director, Child Neurology Residency @StraussHeadache No disclosures
More informationOccipital Nerve Stimulation
Occipital Nerve Stimulation Policy Number: 7.01.125 Last Review: 5/2018 Origination: 5/2006 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for
More informationTikrit University College of Dentistry Dr.Ban I.S. head & neck anatomy 2 nd y.
Lec [3]/The scalp The scalp extends from the supraorbital margins anteriorly to the nuchal lines at the back of the skull and down to the temporal lines at the sides. The forehead, from eyebrows to hairline,
More informationSafety and efficacy of cervical 10 khz spinal cord stimulation in chronic refractory primary headaches: a retrospective case series
Lambru et al. The Journal of Headache and Pain (2016) 17:66 DOI 10.1186/s10194-016-0657-2 The Journal of Headache and Pain SHORT REPORT Open Access Safety and efficacy of cervical 10 khz spinal cord stimulation
More information